The FDA approved Lilly’s Zepbound for chronic weight management, which is a powerful new option for weight loss. Check out their Press release.
Is there a difference between Zepbound and Mounjaro?
There is no difference between them. They are exactly the same drug, which is Tirzepatide, a GLP-1 and GIP receptor agonist.
Lilly did this, so MD’s can prescribe Zepbound for weight loss only, Mounjaro was approved for diabetics and was not FDA approved for just weight loss. This is similar to the Ozempic and Wegovy story, where Novo Nordisk had to create Wegovy for weight loss after marketing Ozempic for diabetics, even though they are exactly the same drug (Semaglutide).
WeGovy and Ozempic have different dosages. While for Mounjaro and Zepbound, they are the exact same dosage concentrations of 2.5, 5, 7.5, 10, 12.5, and 15 mg subcutaneous self-injectable pens.